NCB-0846

NCB-0846 is an orally active, selective inhibitor for Wnt, that inhibits Traf2- and Nck-interacting kinase (TNIK) with an IC50 of 21 nM. NCB-0846 blocks TGF-β signaling pathway by inhibiting SMAD2/3 phosphorylation and nuclear translocation[1][2].

Product Specifications

CAS Number

[1792999-26-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAP4K; TGF-beta/Smad; Wnt

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NCB-0846.html

Purity

99.61

Solubility

DMSO : ≥ 30 mg/mL

Smiles

O[C@@H](CC1)CC[C@@H]1OC2=CC=CC(C=N3)=C2N=C3NC4=CC=C(N=CN5)C5=C4

Molecular Formula

C21H21N5O2

Molecular Weight

375.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Masuda M, et al. TNIK inhibition abrogates colorectal cancer stemness. Nat Commun. 2016 Aug 26;7:12586.|[2]Sugano T, et al., Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J Cancer. 2021 Jan;124 (1) :228-236.